Overview
- A federal jury in the Central District of California found Apple liable for infringing Masimo’s intellectual property and awarded $634 million in damages.
- The verdict centers on U.S. Patent No. 10,433,776 covering blood‑oxygen monitoring technology used in Apple Watch devices, with jurors finding related features such as training mode and heart‑rate notifications violated the patent.
- Apple said it disagrees with the decision and will appeal, arguing that many Masimo patents were invalid and that the patent at issue expired in 2022 and reflects older patient‑monitoring technology.
- Masimo hailed the ruling as an important victory for protecting its innovations and intellectual property.
- The dispute began in 2020 and included a 2023 U.S. ITC ruling that briefly halted U.S. sales of Apple Watch Series 9 and Ultra 2 until Apple removed or redesigned the contested technology.